
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Device-assisted Enteroscopy: National Irish Data Support a Centralized High-Volume Model to Achieve Performance Targets</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">
<div class="mindmap">
<details><summary><strong>Device-assisted Enteroscopy: National Irish Data Support a Centralized High-Volume Model to Achieve Performance Targets</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Source: Endoscopy International Open 2026; 14: a27779128</li>
<li style="margin-left: 0px;">Topic: Device-Assisted Enteroscopy (DAE) Services in Ireland — Performance Evaluation Against ESGE KPIs</li>
<li style="margin-left: 0px;">Author(s): Costigan C, Connaughton R, Sihag S, Leung E, Butler T, O&#x27;Hara FJ, Hall B, McNamara D</li>
</ul>
<details><summary><strong>1. Introduction and Background</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Device-assisted enteroscopy (DAE) provides effective diagnosis/treatment for small bowel disorders since its introduction</li>
<li style="margin-left: 0px;">DAE often serves as therapeutic arm following less-invasive small bowel capsule endoscopy (SBCE)</li>
<li style="margin-left: 0px;">European Society of Gastrointestinal Endoscopy (ESGE) published DAE guidance in 2015, quality-assurance guidelines with KPIs in 2019, and updated performance measures in 2025</li>
<li style="margin-left: 0px;">Study aim: review national DAE services in Ireland against international KPIs and determine practice elements for future development</li>
</ul>
</div></details>
<details><summary><strong>2. Study Methods and Design</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Dual-center, retrospective analysis of both Irish enteroscopy centers (Tallaght University Hospital and Connolly Hospital Blanchardstown)</li>
<li style="margin-left: 0px;">Study period: January 2015 to May 2024 (Tallaght from 2015; Connolly from 2021)</li>
<li style="margin-left: 0px;">Data collected via GI Reporting Tool (Unisoft) or EndoRAAD systems</li>
<li style="margin-left: 0px;">Conscious sedation procedures performed in endoscopy suites with endoscopist-administered sedation</li>
<li style="margin-left: 0px;">General anesthetic cases performed in surgical theater of adjacent day hospital (unstable/multimorbid patients excluded)</li>
<li style="margin-left: 0px;">No access to deep sedation in Irish endoscopy suites or regular surgical theater space for enteroscopy</li>
<li style="margin-left: 0px;">Decision for prolonged/repeat procedures sedation type at endoscopist discretion</li>
<li style="margin-left: 0px;">Demographic, procedure, and follow-up data anonymized and combined; analyzed using chi-square, Fisher exact test, or logistical regression</li>
<li style="margin-left: 0px;">Study approved as service evaluation in both hospitals</li>
</ul>
</div></details>
<details><summary><strong>3. Patient Demographics and Cohort Characteristics</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Total studies reviewed (ITT)</strong>: 1,014 DAE studies</li>
<li style="margin-left: 0px;"><strong>Excluded from per-protocol analysis (n=73)</strong>:</li>
<li style="margin-left: 20px;">Inadequate bowel preparation: 29</li>
<li style="margin-left: 20px;">Ileal intubation failure due to looping: 16</li>
<li style="margin-left: 20px;">Technical failure impeding overtube advancement: 5</li>
<li style="margin-left: 20px;">Anatomical stenosis (esophageal/anal): 5</li>
<li style="margin-left: 20px;">Poor patient tolerance: 8</li>
<li style="margin-left: 20px;">Food bolus in stomach: 5</li>
<li style="margin-left: 20px;">RDBE stopped after bleeding malignant colon lesion: 1</li>
<li style="margin-left: 20px;">Panic attack with withdrawal consent: 1</li>
<li style="margin-left: 20px;">Incomplete EPRs: 3</li>
<li style="margin-left: 0px;"><strong>Final cohort (PP analysis)</strong>: 941 studies on 798 individual patients</li>
<li style="margin-left: 0px;"><strong>Gender distribution</strong>: 548 (58%) male</li>
<li style="margin-left: 0px;"><strong>Mean age</strong>: 61 ± 17 years (range 17–91)</li>
<li style="margin-left: 0px;"><strong>Procedure distribution</strong>:</li>
<li style="margin-left: 20px;">Anterograde DBE (ADBE): 745 (79%)</li>
<li style="margin-left: 20px;">Retrograde DBE (RDBE): 196 (21%)</li>
</ul>
<details><summary><strong>3.1 Center-Specific Demographics</strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Parameter</th>
<th>TUH</th>
<th>CHB</th>
<th>Total</th>
</tr></thead>
<tbody>
<tr>
<td>Total procedures (ITT)</td>
<td>840</td>
<td>174</td>
<td>1,014</td>
</tr>
<tr>
<td>Included (PP)</td>
<td>789/840 (94%)</td>
<td>152/174 (87%)</td>
<td>941/1014 (93%)</td>
</tr>
<tr>
<td>Male (%)</td>
<td>462 (59%)</td>
<td>86 (56.5%)</td>
<td>548 (58%)</td>
</tr>
<tr>
<td>Mean age ± SD</td>
<td>60 ± 18</td>
<td>61 ± 16</td>
<td>61 ± 17</td>
</tr>
<tr>
<td>Anterograde</td>
<td>616 (78%)</td>
<td>129 (85%)</td>
<td>745 (79%)</td>
</tr>
<tr>
<td>Retrograde</td>
<td>173 (22%)</td>
<td>23 (15%)</td>
<td>196 (21%)</td>
</tr>
<tr>
<td>Single balloon</td>
<td>77 (10%)</td>
<td>0</td>
<td>77 (8%)</td>
</tr>
<tr>
<td>Double balloon</td>
<td>712 (90%)</td>
<td>152 (100%)</td>
<td>864 (92%)</td>
</tr>
<tr>
<td>Prior capsule findings</td>
<td>528 (67%)</td>
<td>115 (76%)</td>
<td>643 (68%)</td>
</tr>
<tr>
<td>Conscious sedation</td>
<td>716 (91%)</td>
<td>152 (100%)</td>
<td>868 (92%)</td>
</tr>
<tr>
<td>Diagnostic yield</td>
<td>498 (63%)</td>
<td>94 (62%)</td>
<td>592 (63%)</td>
</tr>
<tr>
<td>Required intervention</td>
<td>332 (42%)</td>
<td>53 (35%)</td>
<td>385 (41%)</td>
</tr>
<tr>
<td>Successful intervention</td>
<td>327/332 (98%)</td>
<td>52/53 (98%)</td>
<td>379/385 (98%)</td>
</tr>
</tbody>
</table>
</div></details>
</div></details>
<details><summary><strong>4. Indications and ESGE Compliance</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Appropriate indication rate</strong>: 883/941 (94%) — <em>target ≥95%</em></li>
<li style="margin-left: 0px;">Most &quot;other&quot; indications included assessment for mucosal healing in Crohn&#x27;s disease when SBCE contraindicated (n=51, 88%)</li>
</ul>
<details><summary><strong>4.1 Indications Breakdown and Yield</strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Indication</th>
<th>Total n=941</th>
<th>% of Total</th>
<th>Yield (%)</th>
</tr></thead>
<tbody>
<tr>
<td>Bleeding on CE</td>
<td>387</td>
<td>41%</td>
<td>305 (79%)</td>
</tr>
<tr>
<td>Abnormal Radiology</td>
<td>191</td>
<td>20%</td>
<td>83 (43%)</td>
</tr>
<tr>
<td>Enteritis on CE</td>
<td>130</td>
<td>14%</td>
<td>70 (54%)</td>
</tr>
<tr>
<td>Known Crohn&#x27;s disease</td>
<td>72</td>
<td>7.5%</td>
<td>57 (79%)</td>
</tr>
<tr>
<td>Mass on CE</td>
<td>54</td>
<td>6%</td>
<td>37 (69%)</td>
</tr>
<tr>
<td>Anemia with normal endoscopy</td>
<td>49</td>
<td>5%</td>
<td>23 (47%)</td>
</tr>
<tr>
<td>Overt bleeding without CE</td>
<td>24</td>
<td>2.5%</td>
<td>16 (67%)</td>
</tr>
<tr>
<td>Obscure bleed without CE</td>
<td>2</td>
<td>0.2%</td>
<td>2 (100%)</td>
</tr>
<tr>
<td>Celiac Assessment</td>
<td>20</td>
<td>2.1%</td>
<td>20 (50%)</td>
</tr>
<tr>
<td>Enteropathy on CE</td>
<td>10</td>
<td>0.9%</td>
<td>4 (40%)</td>
</tr>
<tr>
<td>Other</td>
<td>18</td>
<td>1.9%</td>
<td>7 (39%)</td>
</tr>
<tr>
<td>Suspected Crohn&#x27;s</td>
<td>9</td>
<td>0.9%</td>
<td>6 (67%)</td>
</tr>
<tr>
<td>Submucosal mass on CE</td>
<td>8</td>
<td>0.5%</td>
<td>5 (63%)</td>
</tr>
<tr>
<td>Capsule retention</td>
<td>4</td>
<td>0.4%</td>
<td>3 (75%)</td>
</tr>
<tr>
<td>No indication</td>
<td>4</td>
<td>0.4%</td>
<td>1 (25%)</td>
</tr>
</tbody>
</table>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Yield for valid ESGE indication vs no indication: <strong>64% vs 35%</strong> (P=0.001)</li>
<li style="margin-left: 0px;">Patients with pathology on SBCE had higher yield than those diagnosed by cross-sectional imaging: <strong>69% vs 43%</strong> (P&lt;0.0001)</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>5. Procedure and Technical Success</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Enteroscope types</strong>: DBE used in 864 (92%), SBE in 77 (8%); no spiral enteroscopy performed in Ireland during study period</li>
<li style="margin-left: 0px;"><strong>Pre-procedure imaging</strong>: SBCE performed in advance in 643 patients (68%), cross-sectional imaging in 191 (20%)</li>
<li style="margin-left: 0px;"><strong>Depth of insertion</strong>: documented in 909 procedures (97%); mean depth ADBE: 201 cm ± 101 cm; mean depth RDBE: 101 cm ± 67 cm</li>
<li style="margin-left: 0px;"><strong>Complete enteroscopy</strong>: only three patients achieved complete enteroscopy as single procedure — all had altered anatomy; one further patient had laparoscopic-assisted complete bidirectional enteroscopy</li>
</ul>
<details><summary><strong>5.1 Tattooing and Lesion Marking</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Maximal depth of insertion marked with tattoo in 645 (69%)</li>
<li style="margin-left: 0px;">Lesions requiring further treatment/assessment: 68; tattooed: 62 of 68 (91%)</li>
<li style="margin-left: 0px;">Anterograde enteroscopy placed significantly more tattoos than retrograde: 564/745 (76%) vs 80/196 (41%), P=0.0001</li>
<li style="margin-left: 0px;">No difference in estimated depth or number of cycles between conscious sedation and general anesthetic groups (P=0.8942, P=0.7261)</li>
<li style="margin-left: 0px;">No gender differences in depth or cycles (P=0.2328, P=0.1718)</li>
</ul>
</div></details>
<details><summary><strong>5.2 Sedation Methods and Dosing</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Conscious sedation</strong>: 868 (92%); <strong>General anesthetic</strong>: 73 (8%)</li>
<li style="margin-left: 0px;">Xylocaine spray 50 mg used as topical anesthetic on oropharynx for all anterograde studies</li>
<li style="margin-left: 0px;">Median midazolam dose: 5 mg (IQR 3–7 mg); median fentanyl dose: 75 µg (IQR 50–100 µg)</li>
<li style="margin-left: 0px;">Male gender associated with higher sedation doses: P=0.0245 for midazolam, P=0.0287 for fentanyl</li>
<li style="margin-left: 0px;">Age showed inverse correlation with midazolam dose by logistical regression (P=0.0003); no correlation for fentanyl (P=0.7487)</li>
<li style="margin-left: 0px;">Antispasmodic use: hyoscine n-butyl bromide in 254 patients (27%) — mean dose 15.4 mg; glucagon 1 mg used as alternative in 11 patients with contraindications</li>
</ul>
</div></details>
<details><summary><strong>5.3 Comfort Scores and Patient Tolerance</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Comfort score recorded in 751 conscious sedation cases (87%)</li>
<li style="margin-left: 0px;">Overall mean comfort score: 1.48 ± 0.745</li>
<li style="margin-left: 0px;">Adequate comfort (Modified Gloucester Comfort Scale ≤3): 716 of 751 (95%)</li>
<li style="margin-left: 0px;">Weak negative correlation between comfort and cycles/depth (Spearman R=0.13/R=0.14)</li>
<li style="margin-left: 0px;">No correlation between comfort and medication dose (R=-0.05 for midazolam, R=0.02 for fentanyl)</li>
<li style="margin-left: 0px;">Poor patient tolerance limited duration and extent in 8 of 868 procedures (0.92%) under conscious sedation</li>
</ul>
</div></details>
<details><summary><strong>5.4 Technical Success and Failure Analysis</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Overall technical success rate (ITT)</strong>: 941 of 1014 (93%)</li>
<li style="margin-left: 0px;">Failed procedures more likely to be retrograde than antegrade: 46/242 (19%) vs 27/772 (3.5%), P&lt;0.0001 — primarily due to poor bowel preparation or excess looping in colon</li>
<li style="margin-left: 0px;">Adequate preparation rate significantly lower for RDBEs: 213/242 (88%) vs ADBEs: 767/772 (99%), P&lt;0.0001</li>
<li style="margin-left: 0px;">Ileal intubation rate: 197 of 242 (81%) — no significant difference between sites</li>
<li style="margin-left: 0px;">Significant difference in ileal intubation rate between sedation groups: 175/220 (80%) vs 22/22 (100%), P=0.0177</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>6. Diagnostic and Therapeutic Yield</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Overall diagnostic yield</strong>: 592 of 941 (63%)</li>
<li style="margin-left: 0px;">No difference in overall diagnostic yield between centers (P=0.855) or between DBE and SBE use (P=0.801)</li>
<li style="margin-left: 0px;">ADBE more likely to identify pathology than RDBE: P&lt;0.0001</li>
</ul>
<details><summary><strong>6.1 Findings by Frequency</strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Finding</th>
<th>Total N=941</th>
<th>% of All DAEs</th>
<th>% of Positive Capsules N=592</th>
</tr></thead>
<tbody>
<tr>
<td>Angioectasia</td>
<td>305</td>
<td>32.5%</td>
<td>51.5%</td>
</tr>
<tr>
<td>Enteritis (unspecified)</td>
<td>79</td>
<td>8.5%</td>
<td>13.5%</td>
</tr>
<tr>
<td>Crohn&#x27;s disease</td>
<td>65</td>
<td>7%</td>
<td>11%</td>
</tr>
<tr>
<td>SB polyp</td>
<td>51</td>
<td>5.5%</td>
<td>8.5%</td>
</tr>
<tr>
<td>Dieulafoy</td>
<td>23</td>
<td>2.5%</td>
<td>4%</td>
</tr>
<tr>
<td>Stricture</td>
<td>20</td>
<td>2%</td>
<td>3.5%</td>
</tr>
<tr>
<td>Celiac disease</td>
<td>14</td>
<td>1.5%</td>
<td>2.5%</td>
</tr>
<tr>
<td>— Ulcerative jejunitis</td>
<td>4</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Malignancy (24)</td>
<td>24</td>
<td>2.6%</td>
<td>4%</td>
</tr>
<tr>
<td>— Adenocarcinoma</td>
<td>6</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>— GIST</td>
<td>2</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>— NET</td>
<td>4</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>— Lymphoma</td>
<td>4</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>— Leiomyosarcoma</td>
<td>1</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>— SCC</td>
<td>1</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>— Melanoma</td>
<td>2</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>— &quot;Tumor&quot;</td>
<td>4</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Submucosal mass</td>
<td>10</td>
<td>1%</td>
<td>1.5%</td>
</tr>
<tr>
<td>Anastomotic ulcer</td>
<td>8</td>
<td>0.85%</td>
<td>1.5%</td>
</tr>
<tr>
<td>AVM</td>
<td>3</td>
<td>0.3%</td>
<td>0.5</td>
</tr>
</tbody>
</table>
</div></details>
</div></details>
<details><summary><strong>7. Adverse Events</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Minor adverse events</strong>: 24 cases (2.5%)</li>
<li style="margin-left: 0px;"><strong>Major adverse events</strong>: 9 of 1014 cases (0.88%)</li>
</ul>
<details><summary><strong>7.1 Minor Adverse Events Details</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Mucosal tears/trauma related to overtube advancement</strong>: 19 (2%) — only one case required endotherapy; none required repeat endoscopy, surgical intervention, or hospital admission</li>
<li style="margin-left: 0px;"><strong>Post-polypectomy bleeding</strong>: 4 cases — all managed endoscopically; hemostasis achieved in all cases</li>
<li style="margin-left: 0px;">No patients documented significant drop in serum hemoglobin, presented with complications after procedure, or required repeat endoscopic assessment/intervention</li>
<li style="margin-left: 0px;">One patient developed symptomatic hypoglycemia in recovery room</li>
</ul>
</div></details>
<details><summary><strong>7.2 Major Adverse Events Details</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>7.2.1 Bowel Perforations Related to Stricture Dilatation (n=2)</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Both patients had known history of structuring Crohn&#x27;s disease</li>
<li style="margin-left: 0px;">Both attended for dilatation due to symptoms; both underwent balloon dilatation of short stricture (identified on MRI) after MDT discussion</li>
<li style="margin-left: 0px;">Both patients well interprocedurally with satisfactory endoscopic result</li>
</ul>
<p><strong>Case 1</strong>: Patient had persistent bloating in recovery room; CT revealed small amount of free air without evidence of bowel perforation — diagnosed as iatrogenic microperforation; managed conservatively, observed, discharged after short admission when interval imaging demonstrated resolution of pneumoperitoneum without surgical intervention</p>
<p><strong>Case 2</strong>: Patient had multiple distal small bowel strictures identified on imaging of various severity; due to previous surgeries, MDT decided to proceed with endoscopic dilatation — patient well post-procedure; endoscopic clip placed at dilated stricture site for CT mapping and rediscussion at MDT regarding remaining strictures; discharged from endoscopy department, attended radiology later same day for CT, still feeling well, then contacted to return due to presence of free air — diagnosed with iatrogenic microperforation; managed conservatively, observed, discharged after short admission</p>
</div></details>
<details><summary><strong>7.2.2 Other Major Adverse Events</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Intraprocedure hypotension</strong>: 2 cases — managed by reversal agent, no subsequent inpatient stay required</li>
<li style="margin-left: 0px;"><strong>Intraprocedure hypoxia</strong>: 2 cases — managed by reversal agent, no subsequent inpatient stay required</li>
<li style="margin-left: 0px;"><strong>Massive epistaxis</strong>: 1 case — treated appropriately, discharged same day</li>
<li style="margin-left: 0px;"><strong>Hypothermia and acidemia</strong>: 1 case — due to malfunction with heating unit for water pump; received supportive care, later discharged well</li>
<li style="margin-left: 0px;"><strong>Massive uncontrollable intraprocedural bleeding</strong>: 1 case — patient undergoing DAE for bleeding later died of hemorrhagic shock, deemed unrelated to procedure</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>7.3 Mortality</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">No direct procedure-related mortalities</li>
<li style="margin-left: 0px;">Overall 30-day mortality rate: 1 of 941 (0.1%)</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>8. KPIs and Minor Performance Indices</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>8.1 ESGE Major Performance Measures (ITT Analysis)</strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>KPI</th>
<th>ITT (n=1014)</th>
<th>PP (n=941)</th>
<th>ESGE Target</th>
</tr></thead>
<tbody>
<tr>
<td>Appropriate Indication</td>
<td>955 (94%)</td>
<td>883 (94%)</td>
<td>≥95%</td>
</tr>
<tr>
<td>Tattoo depth of insertion</td>
<td>645 (64%)</td>
<td>645 (69%)</td>
<td>≥80%</td>
</tr>
<tr>
<td>Lesion detection rate (Yield)</td>
<td>594 (59%)</td>
<td>592 (63%)</td>
<td>50%-70%</td>
</tr>
<tr>
<td>Lesions tattooed</td>
<td>63/69 (91%)</td>
<td>62/68 (91%)</td>
<td>≥95%</td>
</tr>
<tr>
<td>Complication rate (total)</td>
<td>34 (3.3%)</td>
<td>31 (3.3%)</td>
<td>&lt;5%</td>
</tr>
<tr>
<td>Complication rate (minor)</td>
<td>24 (2.4%)</td>
<td>24 (2.5%)</td>
<td>N/A</td>
</tr>
<tr>
<td>Complication rate (major) unselected cohort</td>
<td>9 (0.88%)</td>
<td>7 (0.7%)</td>
<td>&lt;1%</td>
</tr>
<tr>
<td>Complication rate (major) post-therapeutics</td>
<td>2/375 (0.5%)</td>
<td>2/375 (0.2%)</td>
<td>&lt;5%</td>
</tr>
<tr>
<td>Adequate patient comfort</td>
<td>735/751 (97.7%)</td>
<td>910/941 (98.5%)</td>
<td>&gt;90%</td>
</tr>
</tbody>
</table>
</div></details>
<details><summary><strong>8.2 Major KPIs by Time Period (ITT)</strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>KPI</th>
<th>2015–2019 N=339</th>
<th>2020–2024 N=675</th>
<th>ESGE Target</th>
</tr></thead>
<tbody>
<tr>
<td>Appropriate Indication</td>
<td>325 (96%)</td>
<td>630 (93%)</td>
<td>≥95%</td>
</tr>
<tr>
<td>Tattoo depth of insertion</td>
<td>174 (51%)</td>
<td>471 (70%)</td>
<td>≥80%</td>
</tr>
<tr>
<td>Lesion detection rate (Yield)</td>
<td>185 (55%)</td>
<td>407 (60%)</td>
<td>50%-70%</td>
</tr>
<tr>
<td>Lesions tattooed</td>
<td>11/13 (85%)</td>
<td>52/56 (93%)</td>
<td>≥95%</td>
</tr>
<tr>
<td>Complication rate (total)</td>
<td>13 (3.8%)</td>
<td>21 (3.1%)</td>
<td>&lt;5%</td>
</tr>
<tr>
<td>Complication rate (minor)</td>
<td>9 (2.7%)</td>
<td>15 (2.2%)</td>
<td>N/A</td>
</tr>
<tr>
<td>Complication rate (major) unselected cohort</td>
<td>4 (1.1%)</td>
<td>6 (0.89%)</td>
<td>&lt;1%</td>
</tr>
<tr>
<td>Complication rate (major) post-therapeutics</td>
<td>1/94 (1%)</td>
<td>1/281 (0.4%)</td>
<td>&lt;5%</td>
</tr>
<tr>
<td>Adequate patient comfort</td>
<td>308/319 (97%)</td>
<td>425/430 (99%)</td>
<td>&gt;90%</td>
</tr>
</tbody>
</table>
</div></details>
<details><summary><strong>8.3 Minor Performance Indices</strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Minor Performance Index</th>
<th>Ireland</th>
<th>ESGE Target</th>
</tr></thead>
<tbody>
<tr>
<td>Proper instructions to patients</td>
<td>100%</td>
<td>≥95%</td>
</tr>
<tr>
<td>Report states insertion depth</td>
<td>909/941 (97%)</td>
<td>≥80%</td>
</tr>
<tr>
<td>Photodocumentation</td>
<td>N/A*</td>
<td>≥95%</td>
</tr>
<tr>
<td>Successful intervention</td>
<td>378/385 (98%)</td>
<td>≥80%</td>
</tr>
<tr>
<td>Adequate bowel preparation</td>
<td>907/941 (96%)</td>
<td>≥95%</td>
</tr>
</tbody>
</table>
<p>*Photodocumentation data unavailable due to 2021 cyberattack on Irish National Health Service Executive servers preventing electronic linking of photodocuments to patient EPRs</p>
</div></details>
<details><summary><strong>8.4 KPI Improvements Summary</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Five of eight major KPIs met</strong> on both ITT and per-protocol basis</li>
<li style="margin-left: 0px;">All minor performance measures met over study duration</li>
<li style="margin-left: 0px;">KPIs consistent between both Irish referral centers</li>
<li style="margin-left: 0px;">Both centers perform high volume (&gt;50 procedures/year) as defined by UK-DEEP paper</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>9. Discussion</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>9.1 Overall Performance and KPI Compliance</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">National Irish DAE study demonstrates good compliance with ESGE KPIs, improving over time</li>
<li style="margin-left: 0px;">Five of eight major KPIs and all minor performance measures met — consistent between both referral centers</li>
<li style="margin-left: 0px;">Both Irish high-volume centers comparable to three high-volume UK centers from DEEP-UK study; all performed better than low-volume UK centers</li>
<li style="margin-left: 0px;">Supports centralization of DAE services in high-volume referral centers where human resources and infrastructure can be optimized</li>
<li style="margin-left: 0px;">High-volume model advantages include access to case volume/mix for training and research/innovation</li>
</ul>
</div></details>
<details><summary><strong>9.2 Conscious Sedation vs General Anesthetic</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Conscious sedation used frequently in Ireland: 92% (868); general anesthetic: 8% (73)</li>
<li style="margin-left: 0px;">Mean comfort score adequate at 1.4; only 8 of 941 (0.85%) procedures limited due to intolerance</li>
<li style="margin-left: 0px;">Overall performance not affected by sedation type except ileal intubation rates in retrograde procedures — higher with general anesthesia</li>
<li style="margin-left: 0px;">Potential bias: local strict anesthetic protocols for day case surgery limiting GA access in elderly/comorbid patients (would bias results in favor of GA)</li>
<li style="margin-left: 0px;">Study suggests conscious sedation can be used in majority of cases without impacting performance — differs from recent publications calling for deep sedation or GA for all DAEs</li>
<li style="margin-left: 0px;">Caveat: majority of patients had prior SBCE (68%), suggesting possible bias toward selecting patients with targets requiring intervention in first/third tertile, thereby requiring shorter depth of insertion and shorter procedure</li>
<li style="margin-left: 0px;">However, mean depth of insertion exceeds recently published DEEP-UK study: ADBE 201cm ± 101 cm, RDBE 101 cm ± 67 cm</li>
</ul>
</div></details>
<details><summary><strong>9.3 Endoscopist Experience and Training</strong></summary><div style="padding-left: 20px;">
</div></details>
</div></details>
</div></details>
</div>
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
